Who is the sponsor?
Genentech
Who are the patients?
Patients who have completed participation in certain other LucentisTM clinical studies and meet the eligibility criteria.
How long are the eligible patients enrollment?
3 years
When did participation agreement start at our site?
2005
What is the enrollment goal for the sponsor?
Not stated
Is the enrollment still open?
No. This study is now closed.
What is this study investigating?
Phase III open-label extension study, which allows eligible patients who have completed participation in certain other LucentisTM clinical studies to continue to receive the investigational drug.
How is the treatment administered?
Intravitreal injections.